Company Overview and News

 
 
Tyranna Resources Ltd vends interest in Pilbara Lithium-Gold Project

2016-04-20 proactiveinvestors.com.au
Tyranna Resources Ltd (ASX:TYX) has been allotted 180 million ordinary shares and 90 million $0.01 unlisted options exercisable on or before 30th June 2017 by Mining Projects Group Ltd. The securities are issued as part consideration of Tyranna selling its 90% interest of the Lynas Find assets which are to be renamed as the Pilbara Lithium-Gold Project. A further 90 million shares will be issued when the Pilbara Lithium-Gold tenements are granted.

 
Appendix 3B and cleansing Notice

2016-04-15 asx.com.au

 
Mining Projects Group Ltd is Thursday's ASX Most Traded with 127 million

2016-04-14 proactiveinvestors.com.au
Mining Projects Group Ltd (ASX:MPJ) is a minerals exploration company, currently undertaking exploration for Nickel, Copper and Gold mineralisation in the Kambalda and Fraser Range regions of Western Australia.

 
Results of Meeting

2016-04-14 asx.com.au

 
Mining Projects Group Ltd is Monday's ASX Most Traded with 284 million

2016-04-11 proactiveinvestors.com.au
Mining Projects Group Ltd (ASX:MPJ) is a minerals exploration company, currently undertaking exploration for Nickel, Copper and Gold mineralisation in the Kambalda and Fraser Range regions of Western Australia.

 
Response to ASX Price Query

2016-04-08 asx.com.au

 
Trading Halt

2016-03-23 asx.com.au

 
Mining Projects Group Ltd to acquire mineral asset

2016-03-22 proactiveinvestors.com.au
Mining Projects Group Ltd (ASX:MPJ) is a minerals exploration company, currently undertaking exploration for Nickel, Copper and Gold mineralisation in the Kambalda and Fraser Range regions of Western Australia.

 
Consolidation/Split - MPJ

2016-03-16 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...